{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.2","upperLimit":"6.3","value":"5.3"},{"groupId":"OG001","lowerLimit":"9.9","upperLimit":"21.7","value":"21.7"},{"groupId":"OG002","lowerLimit":"4.2","upperLimit":"8.3","value":"6.4"},{"comment":"The DOR data was not mature at the time of clinical cutoff (i.e., majority of the responders are still ongoing), so the upper confidence interval was not estimable.","groupId":"OG003","lowerLimit":"6.6","upperLimit":"NA","value":"13.0"},{"groupId":"OG004","lowerLimit":"4.2","upperLimit":"7.4","value":"5.5"},{"comment":"The DOR data was not mature at the time of clinical cutoff (i.e., majority of the responders are still ongoing), so the upper confidence interval was not estimable.","groupId":"OG005","lowerLimit":"6.9","upperLimit":"NA","value":"13"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"96"},{"groupId":"OG001","value":"71"},{"groupId":"OG002","value":"34"},{"groupId":"OG003","value":"30"},{"groupId":"OG004","value":"68"},{"groupId":"OG005","value":"51"}],"units":"Participants"}],"description":"DOR was defined as the time from first occurrence of a CR or PR, whichever came first, to first documented PD or death, whichever occurred first. Disease progression was determined on the basis of investigator assessment with use of RECIST v1.1. CR: disappearance of all target lesions. PR: At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of \\>/= 5 mm.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants randomized to the chemotherapy arm received vinflunine, paclitaxel, or docetaxel per the investigators choice. Vinflunine 320 milligrams per square meter (mg/m\\^2), paclitaxel 175 mg/m\\^2, or docetaxel 75 mg/m\\^2 were administered intravenously on Day 1 of each 21-day cycle until disease progression per standard RECIST v1.1 or unacceptable toxicity.","id":"OG000","title":"Chemotherapy (Vinflunine, Paclitaxel, or Docetaxel)"},{"description":"Atezolizumab was administered intravenously at a fixed dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle. Participants received atezolizumab as long as they continued to experience clinical benefit in the opinion of the investigator until unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator.","id":"OG001","title":"Atezolizumab"},{"description":"PD-L1 immunohistochemistry (IHC) score of IC2/3","id":"OG002","title":"IC2/3 Chemotherapy"},{"description":"PD-L1 immunohistochemistry (IHC) score of IC2/3","id":"OG003","title":"IC2/3 Atezolizumab"},{"description":"PD-L1 immunohistochemistry (IHC) score of IC1/2/3","id":"OG004","title":"IC1/2/3 Chemotherapy"},{"description":"PD-L1 immunohistochemistry (IHC) score of IC1/2/3","id":"OG005","title":"IC1/2/3 Atezolizumab"}],"paramType":"MEDIAN","populationDescription":"DOR analyses was performed on the subset of patients who achieved an objective response.","reportingStatus":"POSTED","timeFrame":"Up to approximately 25 months after first participant enrolled","title":"Unconfirmed Duration of Response (DOR) as Determined by the Investigator With Use of RECIST v1.1","type":"SECONDARY","unitOfMeasure":"months"}